Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019

• Published in: BJU international 2023-11, Vol.132 (5), p.541-553
• Main Authors: Conroy, Samantha, Catto, James W.F., Bex, Axel, Brown, Janet E., Cartledge, Jon, Fielding, Alison, Jones, Rob J., Khoo, Vincent, Nicol, David, Stewart, Grant D., Sullivan, Mark, Tran, Maxine G.B., Woodward, Rose, Cumberbatch, Marcus G.
• Format: Article
• Language: English
• Subjects: Cancer therapies; Diagnosis; Immunotherapy; Kidney cancer; Kidneys; Patients; Radiation therapy; Renal cell carcinoma
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/bju.16128

ObjectivesTo report the NHS Digital (NHSD) data for patients diagnosed with kidney cancer (KC) in England. We explore the incidence, route to diagnosis (RTD), treatment, and survival patterns from 2013 to 2019.Materials and MethodsData was extracted from the Cancer Data NHSD portal for International Classification of Diseases, 10th edition coded KC; this included Cancer Registry data, Hospital Episode Statistics, and cancer waiting times data.ResultsRegistrations included 66 696 individuals with KC. Incidence of new KC diagnoses increased (8998 in 2013, to 10 232 in 2019), but the age‐standardised rates were stable (18.7–19.4/100 000 population). Almost half of patients (30 340 [45.5%]) were aged 0–70 years and the cohort were most frequently diagnosed with Stage 1–2 KC (n = 26 297 [39.4%]). Most patients were diagnosed through non‐urgent general practitioner referrals (n = 16 814 [30.4%]), followed by 2‐week‐wait (n = 15 472 [28.0%]) and emergency routes (n = 11 796 [21.3%]), with older patients (aged ≥70 years), Stage 4 KCs, and patients with non‐specified renal cell carcinoma being significantly more likely to present through the emergency route (all P